In contrast, enavatuzumab treatment of cocultures of PBMCs with any of the four TweakR-expressing tumor cell lines resulted in activation of both monocytes and NK cells, as defined by upregulation of CD54 and downregulation of CD16 on both cell types (Figure 1(b)). The gene discussed is TNFRSF12A; the disease is neoplasm.